By a News Reporter-Staff News Editor at Pharma Business Week A new study on Eye Diseases and Conditions - Retinal Vein Occlusion is now available. According to news reporting originating from Gujarat, India, by NewsRx correspondents, research stated, "This subgroup analysis of the RE-ENACT study evaluates the effectiveness of Razumab (the world's first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) in Indian patients with retinal vein occlusion (RVO). The data on patients with RVO who had received >= 3 injections of Razumab between January and August 2016 were analyzed."
Our news editors obtained a quote from the research from Intas Pharmaceuticals Ltd., "Endpoints were: improvement in best corrected visual acuity (BCVA), and a decrease in central macular thickness (CMT), intraretinal fluid (IRF), and subretinal fluid (SRF) from baseline at weeks 4, 8, and 12. Of 160 patients, the majority (61.87%) were men. The mean (+/- SE) BCVA improved from baseline (0.76 +/- 0.04) to week 4 (0.73 +/- 0.03; p = 0.0656), which attained significance at week 8 (0.55 +/- 0.02; p< 0.0001) and week 12 (0.47 +/- 0.02; p< 0.0001). The mean (+/- SE) CMT significantly decreased from baseline (447.60 +/- 10.91 mu m) to week 4 (431.84 +/- 10.92 mu m; p = 0.0028), week 8 (339.28 +/- 8.12 mu m; p< 0.0001), and week 12 (298.23 +/- 6.68 mu m; p< 0.0001). The proportion of patients with IRF and SRF significantly (p < 0.0001) decreased from baseline to weeks 4, 8, and 12 (IRF: from 70.63 to 45.63, 39.38, and 30.00%, respectively; SRF: from 65.63 to 37.50, 28.13, and 24.38%, respectively). A subgroup analysis of branch RVO and central RVO showed similar results. No new safety concerns were observed."
According to the news editors, the research concluded: "Razumab (biosimilar of ranibizumab) effectively improved visual acuity and disease outcomes in patients with RVO in a real-world setting with no new safety concerns."
For more information on this research see: Real-Life Clinical Effectiveness of Razumab (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study. Ophthalmologica, 2019;241(1):24-31. Ophthalmologica can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland. (Karger - www.karger.com/; Ophthalmologica - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=224269)
The news editors report that additional information may be obtained by contacting S. Sharma, Intas Pharmaceut Ltd., Ahmadabad, Gujarat, India. Additional authors for this research include M.A. Khan and A. Chaturvedi (see also Eye Diseases and Conditions - Retinal Vein Occlusion).
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1159/000488602. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)